Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
about
Pharmacokinetic drug interactions in liver disease: An updateRationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDSPhenotype standardization for statin-induced myotoxicityPyridine-Substituted Desoxyritonavir Is a More Potent Inhibitor of Cytochrome P450 3A4 than RitonavirA review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practiceA clinical drug library screen identifies astemizole as an antimalarial agent.Prevalence and characteristics of adverse drug reactions in neurosurgical intensive care patients.Effects of resveratrol on drug- and carcinogen-metabolizing enzymes, implications for cancer prevention.Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAARTComputational and in vitro studies on the inhibitory effects of herbal compounds on human cytochrome P450 1A2.The mibefradil derivative NNC55-0396, a specific T-type calcium channel antagonist, exhibits less CYP3A4 inhibition than mibefradil.Camptothecin attenuates cytochrome P450 3A4 induction by blocking the activation of human pregnane X receptorArtemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan childrenEffects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphismRational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions.The role of CYP3A4 in the biotransformation of bile acids and therapeutic implication for cholestasis.Drug-drug interactions in pharmacologic management of gastroparesis.Mechanism-based inactivation of human cytochrome P450 3A4 by two piperazine-containing compoundsSex differences in drug disposition.Metabolic interactions between prokinetic agents domperidone and erythromycin: an in vitro analysis.Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2.Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazoleGuide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias.Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion.A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer.Pharmacokinetics and interactions of headache medications, part II: prophylactic treatments.Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting.Time-dependent CYP inhibition.Application of chimeric mice with humanized liver for predictive ADME.Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs.Atorvastatin and cardiovascular risk in the elderly--patient considerationsNatural antioxidants in Alzheimer's disease.Drugs as CYP3A probes, inducers, and inhibitors.Cytochromes p450 and skin cancer: role of local endocrine pathways.The use of hepatocytes in evaluating time-dependent inactivation of P450 in vivo.Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressantRitonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.Long-term and per rectum disposition of Clarithromycin in the desert tortoise (Gopherus agassizii).In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions.Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration
P2860
Q26774479-6E42CA7A-515D-460A-8B5D-0C8859C46ADAQ26777251-2FF0C032-DCCB-44BD-A8B3-DACA0D53302EQ27020935-436AD5F8-16E8-44A7-8B5D-1C3F34DF0C74Q27677369-5B9E4C2A-EC70-4E60-9D3A-56FFA8840AE0Q27692040-908F92E3-48B3-46A4-B8F7-ADC8255476BCQ33248659-A1AEA0A6-0812-4681-8D3E-E2816BE1EAE5Q33370507-7D737C8C-433C-4120-B1F6-F7D0893F5683Q33771427-4D00A92F-AFF4-4B36-BFAF-2AA6C3AF38C4Q34012749-6437759E-127C-4C8C-88A2-2713AB1DC58CQ34039772-320D2DB6-14B8-4E34-943F-4478F1229214Q34082998-EB98344F-A026-4AFD-A824-109B36FE242EQ34128854-B5161575-C89F-4B34-B463-1AD74525BE56Q34137766-58B7C2F4-6AC8-4EA0-90B6-50888934328DQ34213621-30EA969F-240C-44F2-B877-7A9E56EC64EBQ34233142-280C3663-701A-4B31-88F2-7A2176979FFBQ34357861-56EFE6D9-669D-431F-867E-8EC05407D20AQ34480053-96372A72-75CB-4C93-A7FD-380AAAAE8D54Q34575026-2254DCA9-18D9-49C4-9E04-63CC566EAA58Q34635175-5EBB08CD-97EC-4735-B715-5D3D84CD35ADQ34990495-816B48DC-7CDB-4EB8-8D3F-A38F6F649D55Q35015993-FFECD941-9235-4E0A-B4AA-58EB339EEA3EQ35683989-8EEE075F-64AC-4BB8-8780-AEC0098B2581Q36388073-8A8870CE-7FE6-4F22-AE55-E7D8E79D9B7BQ36553825-95AAAA45-1D0F-4A65-A7F5-1055FF542F18Q36642955-1999784D-EE2F-4578-90A3-96CCFF63A932Q36662893-A0ED566E-C2AA-4675-9CE5-68E612D21EB6Q36668891-22BFBB32-9B53-4CC8-8ACA-ADDA0616B491Q36725214-DCA8C59A-3733-4B44-85CF-8E847D53A300Q36761682-B99A22CF-9956-4C3C-BDF9-3E0CDD34E65FQ36871056-50D0A6CD-662D-42A5-9CFA-7D3BEE7AEAA3Q36897445-493258F0-6DF4-4011-BC0E-0B5C77F7F11CQ37016092-022E4F11-B0E8-412D-BE3C-5B8B66BCC432Q37023996-805AC4D7-4F6D-412D-808E-086FFFAA82A8Q37088368-9A8553FB-6CF4-436C-A7AF-3AA44943189BQ37106069-93A10314-55AF-4F36-92C6-D3AD57E9AF2FQ37177088-CB08470C-DD82-44D5-ABF9-6520BC9DA5BCQ37193103-4F99A30F-2400-4CC1-885E-7BC7A5C766D4Q37223359-049609D5-67C2-46CD-8565-6327DDB8FECFQ37237438-492B2BFE-355A-4B90-852D-BF7FA987A5B3Q37247655-FF9811EB-E6F1-4AD5-8A66-C486DC8A8834
P2860
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
@ast
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
@en
type
label
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
@ast
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
@en
prefLabel
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
@ast
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
@en
P2093
P1476
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs
@en
P2093
Boon Cher Goh
Howard L McLeod
Shufeng Zhou
Sui Yung Chan
P304
P356
10.2165/00003088-200544030-00005
P577
2005-01-01T00:00:00Z
P6179
1038097534